Unique ID issued by UMIN | UMIN000027243 |
---|---|
Receipt number | R000031210 |
Scientific Title | Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularization |
Date of disclosure of the study information | 2017/05/04 |
Last modified on | 2018/07/09 14:34:55 |
Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularization
Anti-VEGF therapy for ocular neovascularization
Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularization
Anti-VEGF therapy for ocular neovascularization
Japan |
retinopathy of prematurity
neovascular glaucome
vasoproliferative tumor
choroidal neovascularization
Ophthalmology |
Others
NO
The effect and safety of bevacizumab therapy on ocular neovascular diseases.
Safety,Efficacy
Change of ocular blood flow at 1 week, 1 months and 3 months from the initial treatment.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Intravitreal injection of Bevacizumab
Not applicable |
Not applicable |
Male and Female
The presence of active ocular neovascularization.
1, high risk of stroke infarction
2, high risk of myocardial infarction
3, ocular infection
20
1st name | |
Middle name | |
Last name | Tadashi Matsumoto |
School of Medicine Toho University
Department of Ophthalmology
6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541
81-3-3762-4151
matsu-t@med.toho-u.ac.jp
1st name | |
Middle name | |
Last name | Tadashi Matsumoto |
School of Medicine Toho University
Department of Ophthalmology
6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541
81-3-3762-4151
matsu-t@med.toho-u.ac.jp
School of Medicine Toho University
Self funding
Self funding
NO
2017 | Year | 05 | Month | 04 | Day |
Unpublished
Terminated
2015 | Year | 04 | Month | 01 | Day |
2015 | Year | 07 | Month | 01 | Day |
2017 | Year | 05 | Month | 03 | Day |
2018 | Year | 07 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031210